IL37 and psoriasis vulgaris: ,122 Four interleukin-23 inhibitors (i.e., ustekinumab, risankizumab, guselkumab, tildrakizumab) are currently approved for the treatment of immune-mediated inflammatory diseases such as plaque psoriasis.97